BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/26/2014 5:16:00 PM | Browse: 1022 | Download: 899
 |
Received |
|
2013-10-07 10:34 |
 |
Peer-Review Started |
|
2013-10-08 08:41 |
 |
To Make the First Decision |
|
2014-01-09 20:17 |
 |
Return for Revision |
|
2014-01-19 20:32 |
 |
Revised |
|
|
 |
Second Decision |
|
2014-03-13 13:49 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2014-03-13 16:47 |
 |
Articles in Press |
|
|
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2014-05-07 19:19 |
 |
Publish the Manuscript Online |
|
2014-05-28 11:45 |
Category |
Oncology |
Manuscript Type |
Topic Highlights |
Article Title |
Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives
|
Manuscript Source |
Invited Manuscript |
All Author List |
Florian Hohla, Thomas Winder, Richard Greil, Ferenc G Rick, Norman L Block and Andrew V Schally |
Funding Agency and Grant Number |
|
Corresponding Author |
Florian Hohla, MD, Ⅲrd Medical Department with Hematology, Medical Oncology, Hemostasis, Rheumatology and Infectious Diseases, Oncologic Center, Center for Clinical Cancer and Immunology Trials, Laboratory of Immunological and Molecular Cancer Research, Paracelsus Medical University of Salzburg, Müllner Hauptstrasse 48, A-5020 Salzburg, Austria. f.hohla@salk.at |
Key Words |
Cytotoxic analogs; Luteinizing hormone-releasing hormone; Growth hormone releasing hormone; Gastrin-releasing peptide; Peptide receptors; Epidermal growth factor receptor; Vascular endothelial growth factor; Targeted treatment; Colorectal cancer |
Core Tip |
Our review evaluates the most recent clinical data on therapeutic reagents designed to target the vascular endothelial growth factor and epidermal growth factor receptor signaling pathways in colorectal cancer. As colorectal cancers express receptors for bombesin/gastrin-releasing peptide, growth hormone-releasing hormone, somatostatin as well as luteinizing hormone-releasing hormone, we review the implications of these pathways in the growth of colorectal cancers and summarize experimental data and clinical studies performed to date with regard to the antiproliferative action of antagonistic peptide analogs of these receptors as well as their cytotoxic analogs and their status as drug candidates for the treatment of metastatic colorectal cancer. |
Publish Date |
2014-05-28 11:45 |
Citation |
Hohla F, Winder T, Greil R, Rick FG, Block NL, Schally AV. Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. World J Gastroenterol 2014; 20(20): 6102-6112 |
URL |
http://www.wjgnet.com/1007-9327/full/v20/i20/6102.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v20.i20.6102 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345